Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 5:06 AM
Ignite Modification Date:
2025-12-25 @ 5:06 AM
NCT ID:
NCT05041127
Brief Summary:
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma. The target patient population will be any chordoma patient 18 years of age with locally unresectable disease or metastatic disease.
Detailed Description:
Primary Objective:
• To evaluate the efficacy of cetuximab in patients with advanced (unresectable) or metastatic, chordoma based on response rate according to RECIST1.1.
Secondary Objectives:
* To evaluate response rate according to Choi criteria
* To evaluate the safety and tolerability of cetuximab for chordoma patients
* To evaluate the progression-free survival (median, at 24 weeks, and 52 weeks) and to determine the overall survival (median).
* To evaluate the ratio of PFS on study compared to PFS from prior treatment
Study:
NCT05041127
Study Brief:
Protocol Section:
NCT05041127